ALT
Altimmune Inc
NASDAQ · Biotechnology
$4.87
-0.05 (-1.02%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 37.6K | 227.0K | 275.34M | 252.74M | 265.40M |
| Net Income | -167,659,958 | -911,745,995 | 25.15M | 22.15M | 19.00M |
| EPS | — | — | — | — | — |
| Profit Margin | -475,295.0% | -451,530.3% | 9.1% | 8.8% | 7.2% |
| Rev Growth | -83.5% | -83.5% | +15.3% | +1.7% | -9.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 43.99M | 46.99M | 48.17M |
| Total Equity | — | — | 261.24M | 234.58M | 252.01M |
| D/E Ratio | — | — | 0.17 | 0.20 | 0.19 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -181,460,471 | -1,041,615,996 | 32.97M | 31.01M | 30.68M |
| Free Cash Flow | — | — | 15.51M | 16.83M | 21.60M |